Spruce Biosciences Reports Q3 2024 Earnings and Updates [Yahoo! Finance]
Spruce Biosciences, Inc. (SPRB)
Company Research
Source: Yahoo! Finance
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focusing on developing and commercializing novel therapies for endocrine and neurological disorders, with a key focus on congenital adrenal hyperplasia (CAH). In their third-quarter 2024 earnings report, Spruce Biosciences highlighted upcoming data releases from significant clinical studies and provided updates on their financial standing, including a cash runway extending through the end of 2025. Key financial metrics reveal a decrease in research and development expenses, down to $6.6 million in the third quarter from $13.5 million in the previous year, influenced by the termination of certain studies and completion of others. Collaboration revenue also declined, with $0.6 million reported this quarter compared to $3.1 million in the same period last year. Meanwhile, the company reported a net loss of $8.7 million for the quarter, showing an improvement from a $12.4 million loss in the third quarter of 2023. L
Show less
Read more
Impact Snapshot
Event Time:
SPRB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SPRB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SPRB alerts
High impacting Spruce Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
SPRB
News
- Spruce Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]Yahoo! Finance
- Spruce Biosciences, Inc. (NASDAQ: SPRB) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $2.00 price target on the stock.MarketBeat
- Spruce Biosciences GAAP EPS of -$0.21 beats by $0.04 Nov. 11, 2024 12:47 PM ET By: Harsh Shukla , SA News Editor [Seeking Alpha]Seeking Alpha
- Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesBusiness Wire
- Spruce Biosciences, Inc. Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Shareholders To Reach Out Accesswire
SPRB
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/12/24 - Form SC
- SPRB's page on the SEC website